DAWN Historical PE Ratio Notes

— Day One Biopharmaceuticals (ticker: DAWN) is a clinical-stage biopharma company focused on developing & commercializing targeted therapies for children, adolescents, & adults with cancers that have historically lacked effective treatments—particularly pediatric and young adult populations. DAWN’s business model means it often operates at a net loss due to heavy R&D spending and a lack of consistent product revenue, as most of its drugs are still in clinical trials. This directly impacts its historical price-to-earnings (PE) ratio: for much of its history, DAWN has likely shown a negative or undefined PE ratio, since earnings have been negative or minimal. Unlike mature companies, early-stage biotechs like DAWN are valued largely on future potential rather than current profits, causing their historical PE ratios—when calculable—to fluctuate and often be high or not meaningful. When you review DAWN's historical PE data, expect there to be gaps (years with no PE ratio at all) or periods with extremely high or negative figures, reflecting the inherent uncertainty and speculative premium often applied by the stock market to emerging biotech companies in their pre-commercial stages.

On this page we presented the Day One Biopharmaceutical Historical PE Ratio information for Day One Biopharmaceutical' stock. The average DAWN historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 9.0. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average DAWN historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this DAWN historical PE result, against the recent PE: when this page was posted on 4/23/2026, the most recent closing price for DAWN had been 21.53, and the most recent quarterly earnings result, annualized, was 1.52. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent DAWN PE on 4/23/2026 based on annualized quarterly EPS was 14.2. Based on DAWN's history, that recent PE is elevated relative to the historical average, with the recent PE 57.8% higher than the historical average PE across our data set for Day One Biopharmaceutical.

For self directed investors doing their due diligence on DAWN or any other given stock, valuation analysis for DAWN can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Day One Biopharmaceutical PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for DAWN. Thanks for visiting, and the next time you need to research DAWN Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.